Literature DB >> 12520556

Non-inferiority trials: the 'at least as good as' criterion.

Larry L Laster1, Mary F Johnson.   

Abstract

To demonstrate in a clinical trial that a new or experimental therapy (et) is 'at least as good as' a standard therapy (st), a statistical test or confidence interval procedure must rule out clinical inferiority with a high probability. The term 'at least as good as' implies equivalent but not necessarily superior efficacy. As it is statistically impossible to demonstrate equivalence (that is, prove the null hypothesis of no difference), Blackwelder proposed a one-sided significance test to reject the null hypothesis that standard therapy is better than experimental therapy by a clinically acceptable amount, delta(BW). In this paper, Blackwelder's approach is redefined in terms of the ratio of two means (R(True)= mu(et)/mu(st)) based on a continuous variate with higher values denoting greater improvement. The ratio-based equivalents to Blackwelder's hypotheses will be shown. The ratio parameter has the benefit of being available as a dimensionless percentage, not tied to a specified difference in means. Thus, a study can be sized to assure, with high probability, that the experimental therapy is 'at least' (R(LB)x100) per cent 'as effective as' the standard therapy, where R(LB) is the selected lower bound on the percentage effectiveness. A practical rationale is given for defining non-inferiority as a high fraction or percentage of the standard drug's efficacy, both in terms of statistical efficiency and medical relevance. For most typical 'at least as good as' applications (when R(LB)<R(True) < or =1), the ratio formatted test of H(0):R(True)< or =R(LB) is shown to be more efficient than Blackwelder's test of H(0): mu(st) - mu(et) > or = delta(BW), thereby requiring smaller sample sizes to detect the directionally based non-null alternatives contained in H(1): mu(et)/mu(st)>R(LB) or, equivalently, mu(st) - mu(et)<delta(BW). Further, when R(True)= 1.0, tests of Blackwelder's hypotheses, their ratio-based equivalents and conventional superiority can be evaluated for comparative efficiency. Testing H(0):R(True)< or =R(LB) with single-sided critical region of size alpha, versus H(1):R(True)>R(LB), is shown to be more efficient than excluding R(LB) from the lower limit of a 100(1-2alpha) per cent two-sided symmetric confidence interval centred by R. Relevant examples will be presented. Copyright 2003 John Wiley & Sons, Ltd.

Mesh:

Year:  2003        PMID: 12520556     DOI: 10.1002/sim.1137

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

Review 1.  FDA critical path initiatives: opportunities for generic drug development.

Authors:  Robert A Lionberger
Journal:  AAPS J       Date:  2008-02-20       Impact factor: 4.009

2.  Challenges in the design and analysis of non-inferiority trials: a case study.

Authors:  Valerie Durkalski; Robert Silbergleit; Daniel Lowenstein
Journal:  Clin Trials       Date:  2011-09-15       Impact factor: 2.486

3.  Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

Authors:  Ralph L Sacco; Hans-Christoph Diener; Salim Yusuf; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam Vandermaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

4.  Non-inferiority clinical trials: Practical issues and current regulatory perspective.

Authors:  Sandeep K Gupta
Journal:  Indian J Pharmacol       Date:  2011-07       Impact factor: 1.200

5.  Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach.

Authors:  A C Bouman; A J ten Cate-Hoek; B L T Ramaekers; M A Joore
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

6.  Optimal contrast analysis with heterogeneous variances and budget concerns.

Authors:  Show-Li Jan; Gwowen Shieh
Journal:  PLoS One       Date:  2019-03-26       Impact factor: 3.240

7.  Working Memory Capacity of Biological Motion's Basic Unit: Decomposing Biological Motion From the Perspective of Systematic Anatomy.

Authors:  Chaoxian Wang; Yue Zhou; Congchong Li; Wenqing Tian; Yang He; Peng Fang; Yijun Li; Huiling Yuan; Xiuxiu Li; Bin Li; Xuelin Luo; Yun Zhang; Xufeng Liu; Shengjun Wu
Journal:  Front Psychol       Date:  2022-03-22

8.  The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial.

Authors:  Arina J Ten Cate-Hoek; Annemieke C Bouman; Manuela A Joore; Martin Prins; Hugo Ten Cate
Journal:  BMJ Open       Date:  2014-09-04       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.